Drugs / P38 Inhibitor (4)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00303563 | Apr 2006 → Dec 2007 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00316771 | Nov 2005 → Mar 2008 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P38 Inhibitor (4) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00316771 ↗ |
| Action | Inhibit | “P38 Inhibitor (4)” NCT00303563 ↗ |
| Route | Oral | “50mg po qd” NCT00303563 ↗ |